Search

Purpose: We investigated whether selenium supplementation improves quality-of-life (QoL) in patients with autoimmune thyroiditis (ID:NCT02013479)., Methods: We included 412 patients ≥18 years with serum thyroid peroxidase antibody (TPOAb) level ≥100 IU/mL in a multicentre double-blinded randomised clinical trial. The patients were allocated 1:1 to daily supplementation with either 200 μg selenium as selenium-enriched yeast or matching placebo tablets for 12 months, as add-on to levothyroxine (LT4) treatment. QoL, assessed by the Thyroid-related Patient-Reported-Outcome questionnaire (ThyPRO-39), was measured at baseline, after six weeks, three, six, 12, and 18 months., Results: In total, 332 patients (81%) completed the intervention period, of whom 82% were women. Although QoL improved during the trial, no difference in any of the ThyPRO-39 scales was found between the selenium group and the placebo group after 12 months of intervention. In addition, employing linear mixed model regression no difference between the two groups was observed in the ThyPRO-39 composite score (28.8 [95%CI:24.5-33.6] and 28.0 [24.5-33.1], respectively; P=0.602). Stratifying the patients according to duration of the disease at inclusion, ThyPRO-39 composite score, TPOAb level, or selenium status at baseline did not significantly change the results. TPOAb levels after 12 months of intervention were lower in the selenium group than in the placebo group (1995 [95%CI:1512-2512] vs. 2344 kIU/L [1862-2951]; P=0.016) but did not influence LT4 dosage or free triiodothyronine/free thyroxin ratio., Conclusion: In hypothyroid patients on LT4 therapy due to autoimmune thyroiditis, daily supplementation with 200 μg selenium or placebo for 12 months improved QoL to the same extent.

Introduction: We analyzed the trend in body mass index (BMI) as well as in the prevalence of overweight and obesity among Danish adults, mainly women, from 1997/1998 to 2004/2005 and evaluated any regional differences., Material and Methods: Data were drawn from two cross-sectional population-based studies conducted in parallel in Aalborg and Copenhagen from 1997/1998 and 2004/2005. Height and weight were measured in a total of 7,487 participants in the two cohorts., Results: In the total cohort, we found no significant difference in BMI from 1997/1998 to 2004/2005 (p = 0.828). There was an increase in BMI in Aalborg of 0.32 (p = 0.030), while in Copenhagen we observed a statistically significant decrease in BMI of 0.30 (p = 0.017). The difference in change over time in BMI between the two regions was significant (p = 0.002). Also the difference in the trend in prevalence of overweight and obesity was statistically significant between the two cities (p = 0.010)., Conclusion: Our results indicate that the obesity epidemic is leveling off - at least among women - and that it may even be receding in Copenhagen. Nevertheless, the absolute average BMI values and the prevalence of overweight and obesity in both cities are high which underlines the need for further initiatives to prevent obesity-related health risks in the future., Funding: The DanThyr studies were supported by funding from the Tømmerhandler Vilhelm Bang Foundation, the Copenhagen Corporation Research Foundation, the 1991 Pharmacy Foundation, the Danish Medical Foundation, the Health Insurance Foundation, the Agnes and Knut Mørk Foundation, the Wedel Wedelsborg Foundation, the Ortho-Clinical Foundation and BRAHMS Diagnostica., Trial Registration: not relevant.